Despite recent market surges, there is buy replica watches no doubt we are living in volatile times. By the end of last week, this volatility was once again raising its head as the markets fell sharply.
However, this fall was tempered somewhat by replica watches for sale the release of economic data that showed a stronger than expected performance manufacturing sector. Recent earnings reports have also given reason for optimism. S&P listed companies’ earnings reports were up 46% year-on-year in the first quarter, well above the 20% that was forecasted.
According to Goldman Sachs strategist cheap Replica Watches David Kostin, this positivity is providing support for equities in an uncertain market.
Despite such unpredictability, there are three still 3 stocks that Goldman Sachs is forecasting as having a potential upside of over 100%. Wall Street seems to agree as well, with each stock having a “strong-buy” consensus rating.
1 Relmada Therapeutics
Mental Health is a major sector of the pharmaceutical industry. Antidepressant sales are expected to exceed $18.5 billion by 2027.
Relmada Therapeutics is a clinical-stage pharmaceutical company that specializes in the central nervous system. Currently in the pipeline is a drug known as REL-107, which is an NMDA receptor channel blocker that is under development as a treatment for major depressive disorders.
This drug is now undergoing trials which began in December of last year. Last month the testing program was expanded with a further two studies added and a fourth study is set to begin later this year.
The stock is covered in Goldman Sachs by analyst Andrea Tan, who gives it a buy rating with a target price of $78. This implies a 103% upside over the next year.
2 Agiliti
Agiliti is a company that provides a range of hardware to the medical industry, specializing in hospital equipment. Agiliti’s product range includes beds, bariatrics, ventilators, therapy mattresses, patient monitors, medical-grade adjustable chairs, and surgical equipment. It also offers all the technical support, engineering, and on-site management to support its equipment.
Agiliti has over 90 service centers and supports over 800,000 medical devices in over 7,000 hospitals.
Agiliti debuted on the NYSE in April of this year in an IPO that had an initial value of $14. It has since released its first quarterly report as a public company. Its top-line revenue was $235 million, up by 31% year on year.
Amit Hazan of Goldman Sachs has given Agiliti a buy rating and a $43 price target, implying a 151% upside for the year to come.
3 Rain Therapeutics
Rain Therapeutics is the final company on the Goldman Sachs list of hot stocks. Rain is a newly public company that has two anti-cancer drugs in the pipeline that take a novel approach to the treatment of the disease.
The drugs of interest are Rain-32, which is already undergoing clinical trials, and RAD52, which is in the preclinical trial stage.
Goldman Sachs analyst Graig Suvannavejh has rated Rain Therapeutics as a big buy. The company put over 7 million shares on the American Public markets at $17 each. Suvannavejh has put a target price of $56 on the company’s stock over the next year, a potential upside of 252%.